BRIEF-Precision Biosciences Announces Initial Safety And Antiviral Activity Of Pbgene-Hbv

Reuters
19 Feb
BRIEF-Precision Biosciences Announces Initial Safety And Antiviral Activity Of Pbgene-Hbv

Feb 19 (Reuters) - Precision BioSciences Inc DTIL.O:

  • PRECISION BIOSCIENCES ANNOUNCES INITIAL SAFETY AND ANTIVIRAL ACTIVITY OF PBGENE-HBV IN THE ELIMINATE-B CLINICAL TRIAL

  • PRECISION BIOSCIENCES INC - PBGENE-HBV SAFE AND WELL TOLERATED IN INITIAL STUDY

Source text: ID:nBw9lDyPZa

Further company coverage: DTIL.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10